A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

PHASE2CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

November 26, 2018

Primary Completion Date

February 7, 2020

Study Completion Date

March 9, 2020

Conditions
Fatty Liver, NonalcoholicNAFLDNonalcoholic Fatty Liver DiseaseNonalcoholic SteatohepatitisDigestive System DiseasesType 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

HTD1801

HTD1801 tablets, 250mg

DRUG

Placebo

tablets manufactured to mimic HTD1801 tablets

Trial Locations (17)

28304

Cumberland Research Associates, Fayetteville

32806

Compass Research, Orlando

33434

Excel Medical Clinical Trials, Boca Raton

34211

Florida Research Institute, Lakewood Rch

37076

Digestive Health Research, Hermitage

38138

Gastro One, Germantown

64131

Kansas City Research Institute, Kansas City

76092

Texas Digestive Disease Consultants, Southlake

78229

Pinnacle Clinical Research, San Antonio

78539

Doctors Hospital at Renaissance, Edinburg

78746

Pinnacle Clinical Research, Austin

85224

Institute for Liver Health, Chandler

85711

Institute for Liver Health, Tucson

85712

Adobe Clinical Research, Tucson

91402

National Research Institute, Panorama City

98195

Harborview Medical Center, Seattle

University of Washington Medical Center, Seattle

All Listed Sponsors
lead

HighTide Biopharma Pty Ltd

INDUSTRY

NCT03656744 - A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) | Biotech Hunter | Biotech Hunter